Comparison of fertility rates of combination of enclomiphene citrate and melatonin with fertility rates of plain enclomiphene citrate in cases of dysovulatory infertility

Monika Singh, Shipra Kumari


Background: Clomiphene citrate, a non-steroidal triphenylethylene compound, is the first line medicine used for ovulation in anovulatory women Worldwide. Objective of this study was to study fertility rates of combination of enclomiphene citrate and melatonin and compare it with fertility rates of plain enclomiphene citrate in cases of dysovulatory infertility.

Methods: A total of 107 cases participated in the study out of which 7 women were excluded from the study. So, the results of 100 women were analyzed. Out of 100 women 50 were of Group A i.e., clomiphene supplemented with melatonin group and 50 were in Group B which was clomiphene only group with no supplementation. Cases were followed for three cycles and pregnancy rates in both groups were evaluated.

Results: Study demonstrated the potential benefit of melatonin supplementation in naturally conceived cycles where ovulation induction was given by enclomiphene citrate. The ovulation rates were comparable in both study versus control group (68% versus 66%) while there was increase in pregnancy rate in melatonin group (36% versus 24%). However, difference between pregnancy rates in both the groups failed to reach statistically significant levels (p value 0.4065).

Conclusions: The adjuvant role of melatonin with enclomiphene citrate in cases of dysovulatory infertility in improving pregnancy rates, which is due to strong anti-oxidant effect of melatonin which in turn reduces oxidative stress thus resulting in good quality oocyte production.


Antioxidant, Enclomiphene citrate, Melatonin, Oxidative stress

Full Text:



Hughes E, Brown J, Collins JJ, Vanderkerchove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev. 2010;(1):CD00005.

Wood S, Quinn A, Troupe S, Kingsland C, Lewis-Jones I. Seasonal variation in assisted conception cycles and the influence of photoperiodism on outcome in in-vitro fertilization cycles. Hum Fertil. 2006;9:223-9.

Tamura H, Takasaki A, Taketani T, Tanabe M, Kizuka F, Lee L, et al. The role of melatonin as an antioxidant in the follicle. J Ovarian Res. 2012;5:5.

Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Binding of 3H-melatonin to calmodulin. Life Sci. 1993;53:201-7.

Ressmeyer A, Mayo J, Zelosko V, Sáinz R, Tan D, Poeggeler B, et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep. 2003;8:205-13.

Eryilmaz OG, Devran A, Sarikaya E, Aksakal FN, Mollamahmutoglu L, Cicek N. Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems. J Assisted Reprod Genet. 2011;28:9:815-20.

Batioglu AS, Sahin UU, Ozturk N, Unsal E. The efficacy of melatonin administration on oocyte quality. Gynecol Endocrinol. 2012;28:91-3.

Kim MK, Park EA, Kimetal HJ. Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS? Reprod BioMed Online. 2013;26(1):22-9.

Nishihara T, Hashimoto S, Ito K, Nakaoka Y, Matsumoto K, Hosoi Y, et al. Oral melatonin supplementation improves oocyte and embryo quality in women undergoing in vitro fertilization-embryo transfer. Gynecol Endocrinol. 2014;30(5):359-62.

Chaube SK, Shrivastav TG, Prasad S, Tiwari M, Tripathi A, Pandey AN, et al. Clomiphene citrate induces ROS-mediated apoptosis in mammalian oocytes. Open J Apoptos. 2014;3(3):52.